InVivoMAb anti-mouse Vβ4 TCR

Catalog #BE0166
Clone:
KT4
Reactivities:
Mouse

$150.00 - $3,920.00

In stock
Only %1 left

Product Details

The KT4 monoclonal antibody reacts with the Vβ4 TCR (V beta 4 T cell receptor) of most known mouse strains. Vβ4 TCR-expressing cells are CD4 autoreactive T cells which induce autoimmune thyroiditis after elimination of regulatory T-cell subsets. Plate-bound KT4 antibody has been shown to activate Vβ4 TCR-expressing T cells.

Specifications

Isotype Rat IgG2b
Recommended Isotype Control(s) InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Immunogen KT4 B10.D2 mouse T cell clone I3
Reported Applications in vivo administration
Flow cytometry
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <2EU/mg (<0.002EU/μg)
Determined by LAL gel clotting assay
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 μM filtered
Production Purified from tissue culture supernatant in an animal free facility
Purification Protein G
RRID AB_10950191
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
in vivo administration, Flow Cytometry
Beus, J. M., et al. (2013). "Heterologous immunity triggered by a single, latent virus in Mus musculus: combined costimulation- and adhesion- blockade decrease rejection" PLoS One 8(8): e71221. PubMed

The mechanisms underlying latent-virus-mediated heterologous immunity, and subsequent transplant rejection, especially in the setting of T cell costimulation blockade, remain undetermined. To address this, we have utilized MHV68 to develop a rodent model of latent virus-induced heterologous alloimmunity. MHV68 infection was correlated with multimodal immune deviation, which included increased secretion of CXCL9 and CXCL10, and with the expansion of a CD8(dim) T cell population. CD8(dim) T cells exhibited decreased expression of multiple costimulation molecules and increased expression of two adhesion molecules, LFA-1 and VLA-4. In the setting of MHV68 latency, recipients demonstrated accelerated costimulation blockade-resistant rejection of skin allografts compared to non-infected animals (MST 13.5 d in infected animals vs 22 d in non-infected animals, p<.0001 in contrast the duration of graft acceptance was equivalent between non-infected and infected animals when treated with combined anti-lfa-1 adhesion blockade d for p="n.s.)." combination ctla-4-ig costimulation led to prolonged both cohorts>100 d for both, p<.0001 versus costimulation blockade for either while in the non-infected cohort ctla-4-ig or anti-cd154 alone could effectively pair with adhesion to prolong allograft acceptance infected animals prolonged of skin grafts only be recapitulated when anti-lfa-1 and anti-vla-4 antibodies were combined mst>100 d). Graft acceptance was significantly impaired when CTLA-4-Ig alone (no anti-CD154) was combined with adhesion blockade (MST 41 d). These results suggest that in the setting of MHV68 infection, synergy occurs predominantly between adhesion pathways and CD154-based costimulation, and that combined targeting of both pathways may be required to overcome the increased risk of rejection that occurs in the setting of latent-virus-mediated immune deviation.